Thursday, 6 April 2017

Development Landscape for Antibacterial Therapies Drug Development Pipeline Review, 2017 Market Research Report

ResearchMoz added Latest Research Report titled " Antibacterial Therapies Drug Development Pipeline Review, 2017 " to it's Large Report database.

The Antibacterial Drug Market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the bodys immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

Request for Sample PDF of Premium Research Report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=1049122

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 16
Introduction 20
GBI Research Report Coverage 20
Tuberculosis Overview 20
Pneumonia 20
Methicillin-Resistant Staphylococcus aureus (MRSA) 21
Therapeutics Development 22
Tuberculosis 22
Pneumonia 24
Methicillin-Resistant Staphylococcus aureus (MRSA) 33
Therapeutics under Development by Companies 38
Tuberculosis 38
Pneumonia 41
Methicillin-Resistant Staphylococcus aureus (MRSA) 50
Therapeutics under Investigation by Universities/Institutes 55
Tuberculosis 55
Pneumonia 57
Methicillin-Resistant Staphylococcus aureus (MRSA) 60
Pipeline Products Glance 62
Tuberculosis 62

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket Ghumare
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment